Filling the need for trusted information on health issues…

Trending on kff Enrollment Marketplaces Medicare Advantage

Private Sector Involvement

  • your selections
Clear Search

Filter Results

date

Tags

  • results
Blog Reports On Consortium Of Universities For Global Health Annual Conference

The Global Health Technologies Coalition’s (GHTC) “Breakthroughs” blog reports on the Consortium of Universities for Global Health (CUGH) annual conference held last week, highlighting “a panel hosted by the GHTC, which focused on current fiscal and policy realities in the United States that will impact global health research and development…

Five Japanese Drug Makers Form PPP To Accelerate Development Of Drugs, Vaccines For Infectious Diseases

“Five Japanese pharmaceutical giants are teaming up with the Bill & Melinda Gates Foundation and Japan’s government to develop new medicines, vaccines, and diagnostics for infectious diseases in developing countries,” GENNews reports (4/8). “The Global Health Innovative Technology (GHIT) fund will see Takeda, Astellas, Daiichi-Sankyo, Eisai and Shionogi partner with [the] non-profit…

Examining Global Partnerships On World Health Day

Noting Sunday “was World Health Day, and marked the 65th anniversary of the founding of the World Health Organization,” Andrea Durkin, senior director of global government affairs and policy for Abbott, writes in the U.S. Global Leadership Coalition blog, “This year’s theme, high blood pressure, might seem to be a…

Kaiser Family Foundation Report Examines Innovative Financing Mechanisms For Global Health

A new report from the Kaiser Family Foundation, titled “Innovative Financing Mechanisms for Global Health: Overview and Considerations for U.S. Government Participation,” “examines some of the most prominent new financing mechanisms for global health across a broad range of categories, with particular attention to the current level of U.S. government involvement,”…

Much Work Remains To Be Done In Fight Against Malaria

Positive results announced this week from a large clinical trial testing the efficacy of the RTS,S malaria vaccine are “encouraging,” but they are also “a reminder of how much work remains to be done,” an Economist editorial reports. The WHO abandoned its first efforts to eradicate the disease 14 years after setting out to do so in 1955, but “a new wave of enthusiasm,” beginning in 1998 with the establishment of the Roll Back Malaria partnership and culminating with Bill Gates’s call for malaria eradication four years ago, “has helped to lower the number of malaria deaths by 20 percent over the past decade,” the editorial states.

Industry Becoming More Involved In Ensuring Food Security, Conference Attendees Hear

“Food security concerns as the world’s population surpasses seven billion have prompted global companies to become more actively involved in ensuring future supplies, participants at an agricultural conference said on Monday,” Reuters reports. “The increased role has come at a time government involvement is hampered by the global financial crisis and led to fears a private sector-led expansion may focus on products with profit potential and neglect more effective alternatives,” according to the news agency. “‘We need to produce more food. The figures are debatable but we clearly need at least 50 percent more food in the next two or three decades,’ said Ian Crute, chief scientist at Britain’s Agriculture and Horticulture Development Board,” at the CropWorld 2011 conference (Hunt, 10/31).

Guardian Profiles Anglo American CMO’s Efforts To Fight HIV/AIDS

The Guardian profiles Brian Brink, chief medical officer at Anglo American, South Africa’s largest private-sector employer, and the company’s efforts to treat and prevent HIV among its employees. According to the newspaper, “HIV affects 12,000 of its employees, or 16 percent of its 70,000-strong permanent staff.” The Guardian continues, “For Anglo, a healthy workforce is a more loyal and productive one,” which is why it offers HIV testing and treatment free-of-charge to employees, runs HIV prevention programs, and promotes gender equality. “Not only is it a moral imperative to get on top of the AIDS problem, it’s also good for business, and the wider South African economy. The prevalence of AIDS and HIV [the virus that leads to AIDS] probably lops one percent off the country’s GDP,” Brink said (11/3).

Private Sector Companies Should Contribute To GAVI Matching Fund

The GAVI Alliance has “announced a major new initiative aimed at engaging private sector leaders: the GAVI Matching Fund,” through which “the British Government’s Department for International Development (DFID) and the Bill & Melinda Gates Foundation will provide a 100 percent match of contributions to GAVI from corporations and foundations as well as their customers, members and employees,” Bill Roedy, former CEO of MTV Networks and a GAVI Alliance envoy, writes in a post on the Huffington Post’s “Impact” blog. “Together, DFID and the Gates Foundation have pledged $130 million to support this effort, which means there’s the potential to generate $260 million for global childhood immunization efforts,” he notes.

Innovation Needed To Improve Water Delivery Systems

With more than one billion people lacking access to clean and safe water, and waterborne diseases causing 7,000 child deaths every day worldwide, “[i]t’s more important than ever that we be willing to look at old problems and find innovative ways to solve them. The issues of water access, quantity and quality need to be addressed at the same time,” Kevin McGovern and Quincy Jones, chair and honorary chair, respectively, of The Water Initiative (TWI), write in a Huffington Post opinion piece.

Pharmaceutical Industry Should Invest More In NTDs

In this Forbes opinion piece, contributor Sarika Bansal examines “[w]hat needs to happen for the pharmaceutical industry, academic researchers, and other key players [to] begin investing more seriously in” efforts to address neglected tropical diseases (NTDs). She writes, “Since the term [NTD] was coined [in 2005], there has been considerable activity in the neglected disease space from governments, donors, pharmaceutical companies, and nonprofits alike,” but the status quo “has not yet changed nearly enough, and there is ample room for the pharmaceutical industry to invest more in NTDs.”